The dispersion between Novo and Lilly again goes to show the incredible power of competition to dictate stock outcomes: despite Novos excellent financial performance since 2023 (31% growth in 2023, 25% growth in 2024, 48% EBIT margins), the stock has declined because of competition: investors think Eli Lilly is the emerging winner within GLP-1s, given the stronger weight loss profile of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy), and Lillys more attractive weight loss pipeline assets
Although GLP-1 medications are relatively new, several areas of research are generating excitement among lymphatic specialists
This means you can consolidate data from various sources, including workout activities, steps taken, calories burned, and sleep patterns, all in one place
Content and images used with permission from the Journal of Drugs in Dermatology
Curious about how NAD and semaglutide might fit into your health journey
Appetite suppression varies in strength between individuals